Urinary nuclear matrix protein as a marker for transitional cell carcinoma of the urinary tract
Urinary nuclear matrix protein as a marker for transitional cell carcinoma of the urinary tract
复制标题
DOI：
10.1016/s0022-5347(01)65569-1
复制
发表时间：
1996-10-01
影响因子：
6.6
通讯作者：
Hayden, CL
中科院分区：
文献类型：
--
作者：
Carpinito, GA;Stadler, WM;Hayden, CL
目的：本试验的目的是评估尿核基质蛋白 NMP22* 的免疫测定，作为尿路移行细胞癌的指标。材料和方法：三组受试者参加了 NMP22 的试验：1-175 名患有移行细胞癌的受试者，2-117 名患有良性尿路疾病的受试者和 3-375 名健康志愿者。每个受试者在进入研究时提供了一份（3 次）尿液样本用于分析。检测每个样品的 NMP22 水平。结果：在正常健康志愿者和患有良性病症的受试者中，中位 NMP22 水平分别为 2.9 和 3.3 单位/毫升。移行细胞癌患者的尿 NMP22 中位水平显着高于对照组。活动性移行细胞癌患者的中位尿 NMP22 水平显着高于无疾病证据的患者（6.04 单位/毫升与 4.11 单位/毫升，p = 0.027，1 尾 Mann-Whitney U 检验）。我们注意到肿瘤分级、疾病范围或膀胱内治疗对尿液 NMP22 水平没有影响。结论：NMP22 是一种有前景的泌尿肿瘤标志物，用于监测移行细胞癌。核基质蛋白是一类新型肿瘤标志物，代表了开发提高癌症检测和治疗功效的检测方法的基础。
Purpose: The purpose of this trial was to evaluate an immunoassay for urinary nuclear matrix protein, NMP22,* as an indicator for transitional cell carcinoma of the urinary tract.Materials and Methods: Three groups of subjects participated in this trial of NMP22: 1-175 with transitional cell carcinoma, 2-117 with benign urinary tract conditions and 3-375 healthy volunteers. Each subject provided a single (3 voids) urine sample for analysis at the time of study entry. Each sample was assayed for the level of NMP22.Results: In normal healthy volunteers and in subjects with benign conditions median NMP22 levels were 2.9 and 3.3 units per ml., respectively. Median urinary NMP22 levels in patients with transitional cell carcinoma were significantly greater than in comparison subjects. Patients with active transitional cell carcinoma had significantly greater median urinary NMP22 levels than those with no evidence of disease (6.04 versus 4.11 units per ml., p = 0.027, 1-tailed Mann-Whitney U test). We noted no effect of tumor grade, extent of disease or exposure to intravesical therapy on urinary NMP22 levels.Conclusions: NMP22 is a promising urinary tumor marker for monitoring transitional cell carcinoma. Nuclear matrix proteins are a new class of tumor markers that represent the basis for the development of assays with increased efficacy for the detection and treatment of cancer.